Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
81-100 of 604 trials

Duchenne Muscular Dystrophy: GIVINOSTAT Study

We are evaluating the long-term safety and effects of GIVINOSTAT in patients with Duchenne Muscular Dystrophy who have previously been treated with this drug. The study aims to understand its impact on muscle strength, respiratory function, and daily life.

Duchenne Muscular Dystrophy3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Papulopustular Acne: Clindamycin/Tretinoin Gel Study

We are evaluating a new gel with Clindamycin and Tretinoin for treating papulopustular acne. The study compares its effects to an existing treatment and a placebo to see which works best.

Papulopustular Acne≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatology

GVHD Prevention in Elderly AML/MDS Patients: Thymoglobulin vs. Grafalon

We are comparing two treatments to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome receiving stem cell transplants. The goal is to find out which treatment leads to better outcomes after transplantation.

Acute Myeloid LeukemiaMyelodysplastic Syndrome>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematology

Alzheimer's Disease: Rotigotine and Rivastigmine Study

We are testing a combination of rotigotine and rivastigmine to see if it improves thinking skills and daily activities in people with mild to moderate Alzheimer's disease. This study compares the new treatment to rivastigmine with a placebo.

Mild to Moderate Alzheimer's Disease3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteNeurology

Cholestatic Pruritus: Volixibat Study

We are testing a new drug, volixibat, for patients with itching caused by primary biliary cholangitis. The study aims to see if it can reduce itching and improve quality of life compared to a placebo.

Primary Biliary Cholangitis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInternal Medicine

Hydroxychloroquine for Pregnancy Outcomes in Women with Antiphospholipid Antibodies

We are studying whether hydroxychloroquine can improve pregnancy outcomes for women with antiphospholipid antibodies. This research aims to help understand its potential benefits during pregnancy.

Antiphospholipid Antibodies>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesGynecology and ObstetricsInternal Medicine

Small Cell Lung Cancer: Etoposide-Free Chemotherapy with Durvalumab

We are studying a new treatment combining chemotherapy and durvalumab for patients with extensive stage small cell lung cancer. The trial aims to see how well this treatment works and how it affects patients' quality of life.

Extensive Stage Small Cell Lung Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Guselkumab for Active Psoriatic Arthritis Axial Disease

We are studying whether guselkumab can help reduce symptoms in people with active psoriatic arthritis axial disease who have not been treated before. Participants will receive either the medication or a placebo.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

HER2-Expressing Tumors: Trastuzumab Deruxtecan Study

We are studying the safety and effectiveness of Trastuzumab Deruxtecan in patients with advanced HER2-expressing tumors. This research aims to provide insights into new treatment possibilities for these patients.

HER2 Expressing Tumors6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Sotatercept for Children with Pulmonary Artery Hypertension

We are studying the safety and effects of sotatercept in children aged 1 to under 18 with pulmonary artery hypertension. This research aims to improve treatment options for young patients already receiving standard care.

Pulmonary Arterial Hypertension3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyPulmonology

Chronic Kidney Disease in Children: Finerenone Study

We are studying how well finerenone works and its safety for children with chronic kidney disease and proteinuria. This trial will help us understand its effects when used with standard treatments.

ProteinuriaChronic Kidney Disease6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Progressive Pulmonary Fibrosis: Inhaled Treprostinil Study

We are investigating whether inhaled treprostinil can improve lung function in people with progressive pulmonary fibrosis. The study will also assess its safety and impact on overall health.

Progressive Pulmonary Fibrosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPulmonology

Cystic Fibrosis: Long-Term Study of BI 3720931 Gene Therapy

We are monitoring the health of individuals with cystic fibrosis who previously received the BI 3720931 gene therapy. This study aims to assess the long-term safety and effectiveness of the treatment.

Cystic Fibrosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPulmonology

Breast Cancer: MK-2870 with or without Pembrolizumab

We are comparing a new treatment for advanced breast cancer that can't be surgically removed to standard chemotherapy. This study aims to see if the new treatment improves outcomes for patients.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

Non-Small Cell Lung Cancer: V940 and Pembrolizumab Study

We are testing a new treatment combining V940 with pembrolizumab for patients with resected stage II to IIIB non-small cell lung cancer. The study aims to see if this combination improves survival and quality of life compared to a placebo.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: AZD9574 Treatment Study

We are studying the safety and early effectiveness of AZD9574, both alone and with other cancer therapies, for patients with advanced solid tumors. This research aims to improve treatment options for those facing these challenging conditions.

Advanced Ovarian, Breast, Pancreatic, or Prostate CancerHER2+ Metastatic Solid TumorsAdvanced Unresectable or Metastatic Solid TumorsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Colchicine for Heart Health After PCI

We are studying whether colchicine can help reduce serious heart events in patients with coronary artery disease after a heart procedure. This trial compares colchicine to a placebo to see its effects on heart health.

Coronary Artery DiseaseConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyInternal Medicine

Long-Term Study of Delandistrogene Moxeparvovec (SRP-9001)

We are assessing the long-term safety and effectiveness of delandistrogene moxeparvovec in individuals who previously participated in a clinical study. This research aims to understand how the treatment continues to affect participants over time.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Spinal Muscular Atrophy: Risdiplam for Children

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have not improved after gene therapy. This research aims to see if risdiplam can help these patients regain function.

Spinal Muscular Atrophy (SMA)>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics